Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy

Research output: Contribution to journalArticle

Abstract

Recent years have seen an increased effort in the development of peptide based radiopharmaceuticals for nuclear medicine applications in imaging and therapy. This field is of particular interest in the development of new cancer imaging and treatment strategies. Major developments in the molecular biology of cancer have brought forth the discovery of a number of receptor systems and other cell surface molecules that can be utilized as molecular targets for peptide based agents. Although such a strategy is very appealing and shows great potential for application in humans, there are as yet very few radiopharmaceuticals developed based on this scheme that have made it into clinical practice. Many different factors contribute to the generation of a successful radiopharmaceutical. Among these, a thorough and efficient, pre-clinical evaluation process is necessary to single out those lead compounds that show more promise and are most likely to be winners in clinical applications. To maximize the efficacy of pre-clinical testing one must utilize currently available technology to the best extent possible. Expertise in different areas of drug development is indispensable for this type of research. This work will analyze currently available methods utilized to evaluate radiopharmaceuticals being developed, from compound design to evaluation in pre-clinical animal models.

Original languageEnglish
Pages (from-to)3009-3031
Number of pages23
JournalCurrent Pharmaceutical Design
Volume10
Issue number24
DOIs
Publication statusPublished - 2004

Fingerprint

Radiopharmaceuticals
Peptides
Nuclear Medicine
Therapeutics
Molecular Biology
Neoplasms
Animal Models
Technology
Research
Pharmaceutical Preparations

Keywords

  • Animal models
  • Cell lines
  • G-protein coupled receptors
  • Neuroendocrine tumors
  • Nuclear medicine
  • Peptides
  • Radiolabeling
  • Structure

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy. / Aloj, Lui; Morelli, G.

In: Current Pharmaceutical Design, Vol. 10, No. 24, 2004, p. 3009-3031.

Research output: Contribution to journalArticle

@article{e7ac9adb852348dca193babd1b09e59d,
title = "Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy",
abstract = "Recent years have seen an increased effort in the development of peptide based radiopharmaceuticals for nuclear medicine applications in imaging and therapy. This field is of particular interest in the development of new cancer imaging and treatment strategies. Major developments in the molecular biology of cancer have brought forth the discovery of a number of receptor systems and other cell surface molecules that can be utilized as molecular targets for peptide based agents. Although such a strategy is very appealing and shows great potential for application in humans, there are as yet very few radiopharmaceuticals developed based on this scheme that have made it into clinical practice. Many different factors contribute to the generation of a successful radiopharmaceutical. Among these, a thorough and efficient, pre-clinical evaluation process is necessary to single out those lead compounds that show more promise and are most likely to be winners in clinical applications. To maximize the efficacy of pre-clinical testing one must utilize currently available technology to the best extent possible. Expertise in different areas of drug development is indispensable for this type of research. This work will analyze currently available methods utilized to evaluate radiopharmaceuticals being developed, from compound design to evaluation in pre-clinical animal models.",
keywords = "Animal models, Cell lines, G-protein coupled receptors, Neuroendocrine tumors, Nuclear medicine, Peptides, Radiolabeling, Structure",
author = "Lui Aloj and G. Morelli",
year = "2004",
doi = "10.2174/1381612043383511",
language = "English",
volume = "10",
pages = "3009--3031",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "24",

}

TY - JOUR

T1 - Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy

AU - Aloj, Lui

AU - Morelli, G.

PY - 2004

Y1 - 2004

N2 - Recent years have seen an increased effort in the development of peptide based radiopharmaceuticals for nuclear medicine applications in imaging and therapy. This field is of particular interest in the development of new cancer imaging and treatment strategies. Major developments in the molecular biology of cancer have brought forth the discovery of a number of receptor systems and other cell surface molecules that can be utilized as molecular targets for peptide based agents. Although such a strategy is very appealing and shows great potential for application in humans, there are as yet very few radiopharmaceuticals developed based on this scheme that have made it into clinical practice. Many different factors contribute to the generation of a successful radiopharmaceutical. Among these, a thorough and efficient, pre-clinical evaluation process is necessary to single out those lead compounds that show more promise and are most likely to be winners in clinical applications. To maximize the efficacy of pre-clinical testing one must utilize currently available technology to the best extent possible. Expertise in different areas of drug development is indispensable for this type of research. This work will analyze currently available methods utilized to evaluate radiopharmaceuticals being developed, from compound design to evaluation in pre-clinical animal models.

AB - Recent years have seen an increased effort in the development of peptide based radiopharmaceuticals for nuclear medicine applications in imaging and therapy. This field is of particular interest in the development of new cancer imaging and treatment strategies. Major developments in the molecular biology of cancer have brought forth the discovery of a number of receptor systems and other cell surface molecules that can be utilized as molecular targets for peptide based agents. Although such a strategy is very appealing and shows great potential for application in humans, there are as yet very few radiopharmaceuticals developed based on this scheme that have made it into clinical practice. Many different factors contribute to the generation of a successful radiopharmaceutical. Among these, a thorough and efficient, pre-clinical evaluation process is necessary to single out those lead compounds that show more promise and are most likely to be winners in clinical applications. To maximize the efficacy of pre-clinical testing one must utilize currently available technology to the best extent possible. Expertise in different areas of drug development is indispensable for this type of research. This work will analyze currently available methods utilized to evaluate radiopharmaceuticals being developed, from compound design to evaluation in pre-clinical animal models.

KW - Animal models

KW - Cell lines

KW - G-protein coupled receptors

KW - Neuroendocrine tumors

KW - Nuclear medicine

KW - Peptides

KW - Radiolabeling

KW - Structure

UR - http://www.scopus.com/inward/record.url?scp=4544229980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544229980&partnerID=8YFLogxK

U2 - 10.2174/1381612043383511

DO - 10.2174/1381612043383511

M3 - Article

C2 - 15379665

AN - SCOPUS:4544229980

VL - 10

SP - 3009

EP - 3031

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 24

ER -